Crohn’s disease is a debilitating inflammatory bowel disease that chronically affects the lining of the digestive tract and is usually resistant to conventional drug-based treatment. Even with treatment the condition generally progresses to the point where surgery is required in 70% of sufferers. Surgery, however, does not usually provide a cure, with 30% undergoing surgery seeing a recurrence of symptoms within three years, and 60% within 10 years.1
Given the poor prognosis of those diagnosed with Crohn’s disease, some with the condition have been known to experiment with natural alternatives. GreenMedInfo.com have gathered preliminary research on natural interventions for the condition, with probiotics, boswellia and curcumin (a turmeric polyphenol) top on the list. They have also spent a good deal of time reporting on research indicating that wheat is an inflammatory food to the digestive tract and therefore should likely be avoided by anyone with an inflammatory bowel condition.
One potential remedy for Crohn’s disease that we have not yet reported on is cannabis. Animal research already indicates that it can ameliorate colitis, an inflammatory condition of the colon. There is also an established role of cannabis within gastroenterology for the following conditions: “anorexia, emesis, abdominal pain, gastroenteritis, diarrhea, intestinal inflammation, and diabetic gastroparesis.”2 Additionally, a retrospective observational study from 2011 found that 21 of the 30 patients who imbibed inhaled cannabis saw significant improvement, with patients requiring steroid treatment reduced from 26 to 4. [view the full PDF here]
These preliminary results set the groundwork for a new study investigating cannabis in Crohn’s patients published this month in the journal Clinical Gastroenterology and Hepatology and titled, “Cannabis Induces a Clinical Response in Patients With Crohn’s Disease: A Prospective Placebo-Controlled Study.” [view the full PDF here]
In the new study — the first randomized, placebo-controlled, double-blinded study of its kind on the topic — researchers studied 21 patients (mean age 40) with Crohn’s disease who did not respond to drug therapy (steroids, immunomodulators, or anti–tumor necrosis factor-α agents). Patients were randomly assigned to be given cannabis, twice daily, in the form of cigarettes containing 115 mg of (THC) or placebo containing cannabis flowers from which the THC had been extracted.
The study participants were assessed during 8 weeks of treatment and 2 weeks thereafter and saw the following remarkable results:Complete remission (CDAI score, <150) was achieved by 5 of 11 subjects in the cannabis group (45%) and 1 of 10 in the placebo group (10%; P = .43). A clinical response (decrease in CDAI score of >100) was observed in 10 of 11 subjects in the cannabis group (90%; from 330 ± 105 to 152 ± 109) and 4 of 10 in the placebo group (40%; from 373 ± 94 to 306 ± 143; P = .028). Three patients in the cannabis group were weaned from steroid dependency.Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects. [emphasis added]
“Cannabinoids have a profound anti-inflammatory effect, mainly through the CB2 receptor 2]. Cell-mediated immunity was found to be impaired in] chronic marijuana users . A potent anti-inflammatory effect of cannabis was observed in rodents . Studying the functional roles of the endocannabinoid system in immune modulation reveals that it is involved in almost all major immune events. Cannabinoids shift the balance of proinflammatory cytokines and anti-inflammatory cytokines (towards the T helper cell type 2 profiles (Th2 phenotype and suppress cell-mediated immunity, whereas humoral immunity may be enhanced . Therefore, cannabinoids may be used to treat various inflammatory conditions ,including rheumatoid arthritis.” [Source]
For more information on the myriad therapeutic properties of cannabis visit cannabis research database.
GreenMedInfo.com provides cutting-edge, evidence-based natural health information and has one of the internet’s most popular e-newsletters with over 100K subscribers. Register for free here.